(Q53236575)

English

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

scientific article published on 21 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Enrique Gallardo

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

José Luis Pérez-Gracia

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Jose Luis Gonzalez Larriba

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

J Bellmunt

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

C Prior

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

P Maroto

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

D Castellano

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

B Mellado

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

G Aguilar

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

X Villanueva

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

J Albanell

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

21 March 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

2646-2653

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Molecular biology of bladder cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

VEGF receptor expression and signaling in human bladder tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Phase II study of sunitinib in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Multiplexed microsphere-based flow cytometric assays

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

The interleukin-8 pathway in cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Interleukin-8 and human cancer biology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53236575&oldid=1189626782"